Sargramostim


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV Chemotherapy-induced neutropenia 250 mcg/m2/day for ≤42 days as needed. Bone marrow transplantation 250 mcg/m2/day. If engraftment is delayed or has failed, a 14-day course at 250 mcg/m2/day may be given. May repeat course after a 7-day interval if engraftment has not occurred. A 3rd course at 500 mcg/m2/day may be given after another 7-day interval if needed. IV/SC Mobilisation of peripheral blood progenitor cells 250 mcg/m2/day.
Dosage Details
Intravenous
Bone marrow transplantation
Adult: 250 mcg/m2 daily by IV infusion over 2 hr. If engraftment is delayed or has failed, a 14-day course at 250 mcg/m2 daily may be given. Course may be repeated after a 7-day interval if engraftment has not occurred. A 3rd course at 500 mcg/m2/day may be given for 14 days after another 7-day interval, if needed. Further dose increment may not be beneficial.

Intravenous
Chemotherapy-induced neutropenia
Adult: 250 mcg/m2 daily for up to 42 days as required, to be given as IV infusion over 4 hr.

Parenteral
Mobilisation of peripheral blood progenitor cells
Adult: 250 mcg/m2 daily by continuous IV infusion over 24 hr or once daily by SC inj with leucapheresis usually starting on day 5 and continued daily until protocol specified targets are reached. Reduce dose by half if WBC>50,000 cells/mm3. Consider other mobilisation therapy if the numbers of progenitor cells that are collected are inadequate.
Contraindications
Hypersensitivity. Patients with excessive leukaemic myeloid blasts in the bone marrow or peripheral blood (≥10%). 24 hr before or after radiotherapy or chemotherapy.
Special Precautions
Pregnancy; lactation; fluid retention; heart failure; pulmonary disease; any pre-malignant or malignant myeloid condition. Withdraw treatment in patients who develop signs of pulmonary infiltrates. Monitor CBC, renal and hepatic function regularly during therapy. Patients with hypoxia.
Adverse Reactions
Transient hypotension; flushing; bone and musculoskeletal pain; fever, chills, dyspnoea; rash; fatigue; GI effects; anaphylactic reactions, pleural and pericardial effusion; cardiac rhythm abnormalities. Antibodies have been detected.
Overdosage
Overdosage may lead to increased leukocyte counts, dyspnoea, malaise, nausea, fever and rash. Treatment includes discontinuing the drug immediately and monitor for signs of respiratory symptoms and leukocytosis.
Drug Interactions
Action may be potentiated by lithium and corticosteroids.
Action
Description: Sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor, acts as a haematopoietic growth factor stimulating the development of WBC, particularly granulocytes, macrophages and monocytes.
Storage
Store at 2-8°C.
Disclaimer: This information is independently developed by MIMS based on Sargramostim from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in